Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Production of human factor VIII-FL in 293T cells using the bicistronic MGMT(P140K)-retroviral vector

Full text
Fontes, A. M. [1, 2, 3] ; Melo, F. U. F. [2] ; Greene, L. J. [2] ; Faca, V. M. [2] ; Lin, Y. [4, 5] ; Gerson, S. L. [4, 5] ; Covas, D. T. [1, 2, 3]
Total Authors: 7
[1] Univ Sao Paulo, Dept Genet, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Hemoctr Ribeirao Preto, Inst Nacl Ciencia & Tecnol Celulas Tronco & Terap, Hosp Clin, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, Dept Clin Med, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, SP - Brazil
[4] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 - USA
[5] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Cleveland, OH - USA
Total Affiliations: 5
Document type: Journal article
Source: Genetics and Molecular Research; v. 11, n. 1, p. 775-789, 2012.
Web of Science Citations: 2

Hemophilia A is the most common X-linked bleeding disorder; it is caused by deficiency of coagulation factor VIII (FVIII). Replacement therapy with rFVIII produced from human cell line is a major goal for treating hemophilia patients. We prepared a full-length recombinant FVIII (FVIII-FL), using the pMFG-P140K retroviral vector. The IRES DNA fragment was cloned upstream to the P140K gene, providing a 9.34-kb bicistronic vector. FVIII-FL cDNA was then cloned upstream to IRES, resulting in a 16.6-kb construct. In parallel, an eGFP control vector was generated, resulting in a 10.1-kb construct. The 293T cells were transfected with these constructs, generating the 293T-FVIII-FL/P140K and 293T-eGFP/P140K cell lines. In 293T-FVIII-FL/P140K cells, FVIII and P140K mRNAs levels were 4,410 (+/- 931.7)- and 295,400 (+/- 75,769)-fold higher than in virgin cells. In 293T-eGFP/P140K cells, the eGFP and P140K mRNAs levels were 1,501,000 (+/- 493,700)- and 308,000 (+/- 139,300)-fold higher than in virgin cells. The amount of FVIII-FL was 0.2 IU/mL and 45 ng/mL FVIII cells or 4.4 IU/mu g protein. These data demonstrate the efficacy of the bicistronic retroviral vector expressing FVIII-FL and MGMT(P140K), showing that it could be used for producing the FVIII-FL protein in a human cell line. (AU)

FAPESP's process: 08/57877-3 - National Institute of Science and Technology in Cell Therapy
Grantee:Roberto Passetto Falcão
Support type: Research Projects - Thematic Grants
FAPESP's process: 98/14247-6 - Center for Research on Cell-Based Therapy
Grantee:Marco Antonio Zago
Support type: Research Grants - Research, Innovation and Dissemination Centers - RIDC